7,409.25

+26.25

+0.36%

51,326.00

-289.00

-0.56%

27,121.75

+369.75

+1.38%

Russell 2000 Futures

2,735.50

+0.10

+0.00%

4.8370

-0.0570

-1.16%

28.18

+11.57

+69.66%

4,072.60

-40.90

-0.99%

75,967.85

-4,488.72

-5.58%

Crude Oil Dec 26

91.42

+0.90

+0.99%

US Private Equity

10,760.93

-143.81

-1.32%

Shanghai - Delayed Quote CNY

Shenzhen Chipscreen Biosciences Co., Ltd. (688321.SS)

21.56 +0.17 (+0.80%)

As of 9:56:05 AM GMT+8. Market Open.

Chidamide Plus Nivolumab Shows Potential as New Standard of Care in Advanced Melanoma, Reducing Disease Progression Risk by 27% in Global Phase 3 Trial

Business Wire 10d ago

688321.SS
+0.80%
Chipscreen Biosciences Announces NMPA IND Approval for NW001, a PD-L1-Targeted Epigenetic Immune-Modulating Antibody Conjugate

Business Wire 20d ago

688321.SS
+0.80%
Chipscreen Biosciences Announced NMPA Approval of IND for CS43158, an AML Candidate Discovered via the AI-enabled Chemical Genomics Platform

Business Wire 24d ago

688321.SS
+0.80%

Mobilize your Website

View Site in Mobile | Classic

Share by: